VRTX Shares Surge 1.39% on $1 Billion Volume Ranks 98th in U.S. Trading Activity

Vertex Pharmaceuticals (VRTX) saw a 1.39% rise in its share price on Sept. 25, 2025, with a trading volume of $1.00 billion, representing a 73.77% increase from the previous day. This surge placed the stock 98th in terms of trading activity among U.S. equities, highlighting renewed investor interest in the biotech firm.

Recent developments suggest Vertex’s momentum is driven by its pipeline advancements and strategic partnerships. Analysts note that elevated trading volumes often reflect market anticipation of near-term catalysts, such as regulatory updates or clinical trial milestones. However, the absence of explicit guidance from the company in recent communications has left some investors cautious about the sustainability of the upward trend.

To evaluate the performance of high-volume stocks like Vertex, a back-test framework was proposed. The methodology involves sorting all U.S. equities by daily trading volume to form a 500-stock basket, held for one session, and repeated from Jan. 3, 2022, to the present. While the current system processes one security at a time, alternative approaches—such as using a liquid index (e.g., SPY, VTI) or conducting an event study on representative samples—could approximate the strategy within existing constraints.